La catena delle opzioni mostra i dati chiave delle opzioni azionarie di BTC Digital a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per BTC Digital..

BTC Digital (NASDAQ:BTCT) Azioni, Catena delle Opzioni

BTC Digital

Meten Holding Gr

BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations. Geographically, the financial assets of the company is located in the United States, Singapore, Hong Kong and the PRC.

APi Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APG#NYSE">APG</a>) raises FY2025 sales outlook from $7.40 billion-$7.60 billion to $7.65 billion-$7.85 billion vs $7.51 billion estimate.

News

Guidance

APi Group Raises FY2025 Sales Guidance from $7.40B-$7.60B to $7.65B-$7.85B vs $7.51B Est

Belden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) is looking for Q3 GAAP EPS of $1.33-$1.43 vs $1.37 analyst estimate..

Belden Sees Q3 GAAP EPS $1.33-$1.43 vs $1.37 Est

APi Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APG#NYSE">APG</a>) sees Q3 sales of $1.985 billion-$2.035 billion vs $1.93 billion analyst estimate.

APi Group Sees Q3 Sales $1.985B-$2.035B vs $1.93B Est

Belden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) is looking for Q3 Adj EPS of $1.85-$1.95 vs $1.85 analyst estimate. sees sales of $670.000 million-$685.000 million vs $676.904 million analyst estimate.

Belden Sees Q3 Adj EPS $1.85-$1.95 vs $1.85 Est; Sees Sales $670.000M-$685.000M vs $676.904M Est

B of A Securities analyst Michael McGovern maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Buy and raises the price target from $375 to $425.

Price Target

Analyst Ratings

CVNA

B of A Securities Maintains Buy on Carvana, Raises Price Target to $425

Outlook
AGCO now expects full-year 2025 net sales of approximately $9.8 billion. Adjusted operating margins are projected to be approximately 7.5%. Lower production volumes are expected to be partially offset by cost controls and stable engineering expenses. Based on these assumptions, full-year earnings per share are now targeted between $4.75 and $5.00. These estimates incorporate the expected impact of tariffs in effect as of July 31, 2025, along with AGCO's mitigation strategies. Any changes to tariff policies or related responses could affect these projections.

AGCO

AGCO Raises FY2025 Adj EPS Guidance from $4.00-$4.50 to $4.75-$5.00 vs $4.21 Est; Raises FY2025 Sales Guidance from $9.600B to $9.800B vs $9.617B Est

Earnings

Earnings Beats

EMCOR Group Q2 Adj. EPS $6.72 Beats $5.74 Estimate, Sales $4.30B Beat $4.11B Estimate

PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) reported quarterly earnings of $0.38 per share which missed the analyst consensus estimate of $0.39 by 1.81 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.025 billion which beat the analyst consensus estimate of $1.986 billion by 1.94 percent. This is a 7.66 percent increase over sales of $1.881 billion the same period last year.

Earnings Misses

PPL Q2 Adj. EPS $0.38 Misses $0.39 Estimate, Sales $2.025B Beat $1.986B Estimate

2025 Financial Outlook
MGP provided consolidated guidance for fiscal 2025:
<ul>
<li>Sales are projected to be in the range of $520 million to $540 million.</li>
<li>Adjusted EBITDA is expected to be in the range of $105 million to $115 million.</li>
<li>Adjusted basic EPS is expected to be in the $2.45 to $2.75 range, with weighted average basic shares outstanding of approximately 21.4 million, and an effective tax rate of approximately 25%.</li>
<li>Full-year capital expenditures are now expected to be approximately $32.5 million relative to previous expectations of approximately $36 million.</li>
</ul>

MGPI

MGP Ingredients Affirms FY2025 Adj EPS Guidance of $2.45-$2.75 vs $2.49 Est; Affirms FY2025 Sales Guidance of $520.000M-$540.000M vs $532.049M Est

Needham analyst Mike Cikos maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Buy and raises the price target from $35 to $42.

TENB

Needham Maintains Buy on Tenable Holdings, Raises Price Target to $42

Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) reported quarterly earnings of $1.81 per share which beat the analyst consensus estimate of $1.75 by 3.49 percent. This is a 19.08 percent increase over earnings of $1.52 per share from the same period last year. The company reported quarterly sales of $2.543 billion which beat the analyst consensus estimate of $2.513 billion by 1.21 percent. This is a 9.75 percent increase over sales of $2.317 billion the same period last year.

Intercontinental Exchange Q2 Adj. EPS $1.81 Beats $1.75 Estimate, Sales $2.543B Beat $2.513B Estimate

APi Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APG#NYSE">APG</a>) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.37 by 4.56 percent. This is a 20.41 percent decrease over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.99 billion which beat the analyst consensus estimate of $1.90 billion by 4.98 percent. This is a 15.03 percent increase over sales of $1.73 billion the same period last year.

APi Gr Q2 Adj. EPS $0.39 Beats $0.37 Estimate, Sales $1.99B Beat $1.90B Estimate

Belden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) reported quarterly earnings of $1.89 per share which beat the analyst consensus estimate of $1.75 by 8.31 percent. This is a 25.17 percent increase over earnings of $1.51 per share from the same period last year. The company reported quarterly sales of $671.992 million which beat the analyst consensus estimate of $655.927 million by 2.45 percent. This is a 11.20 percent increase over sales of $604.336 million the same period last year.

Belden Q2 Adj. EPS $1.89 Beats $1.75 Estimate, Sales $671.992M Beat $655.927M Estimate

Acadian Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAMI#NYSE">AAMI</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.53 by 21.9 percent. This is a 42.22 percent increase over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $124.900 million which beat the analyst consensus estimate of $117.600 million by 6.21 percent. This is a 15.33 percent increase over sales of $108.300 million the same period last year.

AAMI

Acadian Asset Management Q2 Adj. EPS $0.64 Beats $0.53 Estimate, Sales $124.900M Beat $117.600M Estimate

Cryptocurrency-focused companies Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), which are due to report their second-quarter earnings after Thursday's market close, have seen their stock performances diverge significantly lately.
What happened: Coinbase, the largest cryptocurrency trading platform in the U.S., recorded a strong price action over the last three months.
The stock <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46494592/coinbase-stock-soars-to-all-time-high-on-landmark-crypto-legislation">peaked at an all-time high of $444.65</a>, driven by the passage of the GENIUS Act, also known as the stablecoin bill, and the progress of the CLARITY Act, two major pieces of cryptocurrency legislation.
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/insights/options/25/07/46725172/what-the-options-market-tells-us-about-strategy">What the Options Market Tells Us About Strategy</a>
The company also reaped the benefits of the cryptocurrency bull run, which <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46388685/bitcoin-shatters-all-time-high-to-hit-123000-as-ethereum-cracks-3000-and-xrp-taps-3#:~:text=2%20min%20read-,Bitcoin%20Shatters%20All%2DTime%20High%20To%20Hit%20%24123%2C000%20As%20Ethereum,%243%2C000%20And%20XRP%20Taps%20%243&amp;text=XRP%20faced%20the%20largest%20outflows,price%20over%20the%20same%20period.">drove Bitcoin to an all-time high of $123,000</a>.
Additionally, Coinbase <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45416971/coinbase-becomes-first-pure-play-crypto-stock-in-sp-500-analyst-sees-major-institutional-upside">derived momentum from its inclusion</a> in the S&amp;P 500 Index, the widely used benchmark for the U.S. stock market.&nbsp;
While there was a cooldown in July, the stock's gains over the last three months stood at an impressive 81%.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>3-Month Gains</td>
<td>1-Month Gains</td>
<td>Relative Strength Index</td>
<td>Bull Bear Power Indicator</td>
<td>Moving Average Rating</td>
<td>Overall Technical Rating</td>
<td>Price at Wednesday's market close</td>
</tr>
<tr>
<td>Coinbase</td>
<td>+81.08%</td>
<td>+5.08%</td>
<td>54.94 &#8211; Neutral</td>
<td>−11.44 &#8211; Buy</td>
<td>Buy</td>
<td>Buy</td>
<td>$377.48</td>
</tr>
<tr>
<td>Strategy</td>
<td>+0.70%</td>
<td>+1.35%</td>
<td>43.92 &#8211; Neutral</td>
<td>−25.99 &#8211; Neutral</td>
<td>Sell</td>
<td>Sell</td>
<td>$395.04</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">COIN vs. MSTR comparison/ Source: TradingView</figcaption></figure>
As of this writing, the COIN stock demonstrated a very high Momentum score. Visit <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge Stock Rankings</a> to see how MSTR stacks up on this parameter.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/COIN"><img loading="lazy" decoding="async" width="432" height="197" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31015920/image-495.png" alt="" class="wp-image-1008338" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31015920/image-495.png 432w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31015920/image-495-300x137.png 300w" sizes="(max-width: 432px) 100vw, 432px" /></a></figure>
Bitcoin treasury company Strategy, meanwhile, lagged in this period, growing by just 0.70%. This was in stark contrast to the 22% gains in Bitcoin.
The performance slightly improved in July as the company executed a $2.52 <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46706233/strategy-closes-2-52b-strc-ipo-acquires-21021-bitcoin-at-117k-each">billion initial public offering</a> of preferred stock and utilized the proceeds to purchase additional BTC.
As of this writing, Strategy held 628,791 BTC, acquired at a total cost of $46.8 billion, averaging $73,227 per Bitcoin across all purchases to date.
Price Action: Shares of Coinbase and Strategy rose around 1.40% in after-hours trading, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>
Photo Courtesy: insta_photos on Shutterstock.com
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/previews/25/07/46742773/coinbase-q2-preview-can-white-house-momentum-bitcoin-all-time-highs-help">Coinbase Q2 Preview: Can White House Momentum, Bitcoin All-Time Highs Help?</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

COIN

MSTR

How Coinbase And Michael Saylor's Strategy Stack Up: Crypto Stock Check-Up Ahead Of Q2 Earnings

Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) announced the latest findings on Thursday for blarcamesine, an oral small molecule that could potentially treat <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">early Alzheimer&#8217;s disease</a>.
The data were presented at the 2025 Alzheimer&#8217;s Association International Conference.
The ATTENTION-AD (ANAVEX2-73-AD-EP-004) open-label extension (OLE) Phase 2b/3 treatment trial followed the 48-week ANAVEX2-73-AD-004 double-blind (DB) clinical trial, with a combined duration of up to 192 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44670067/anavex-life-sciences-long-term-trial-data-for-blarcamesine-treatment-slows-cognitive-and-functional-decline-in-alzheimers-patients" rel="noreferrer noopener">Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer&#8217;s Over 3 Years</a>
The trial was designed to evaluate the safety and tolerability of blarcamesine and its long-term effects on cognition (ADAS-Cog13) and function (ADCS-ADL) in participants with early Alzheimer&#8217;s disease.
Blarcamesine-treated patients continue to accrue benefits for up to 4 years.
In the intent-to-treat (ITT) population, delayed-start analysis of treatment with oral blarcamesine was significant for both cognition and function, reflecting the importance of early treatment initiation.
For ADAS-Cog13, a significant difference between the early-start and late-start treatment groups at Week 192 was observed.
Similarly, for ADCS-ADL at Week 192, statistical significance (LS mean difference +4.30, P = 0.0206) was reached, favoring the early-start group.
Additionally, the GWAS-identified population ABCLEAR2, with a global frequency of ~71.7%, showed further improvement in cognition, ADAS-Cog13, and function, ADCS-ADL, respectively.
This clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) of &#8216;time saved&#8217; by the early-start analysis.
In Alzheimer&#8217;s disease clinical trials, &#8216;time saved&#8217; refers to the estimated amount of time a treatment delays the progression of the disease, allowing patients to maintain functionality and independence longer.
Further presentations at the AAIC 2025 Conference featured prespecified Precision Medicine Phase 2b/3 48-week ANAVEX2-73-AD-004 DB trial data on blarcamesine, confirming the upstream mechanism of blarcamesine, restoring impaired autophagy as an early event, preceding amyloid-beta and tau.
A clinical Precision Medicine approach confirmed that the prespecified SIGMAR1 non-mutated population achieved deeper clinical responses to blarcamesine than the respective ITT population.
While in the ITT population, trial participants showed significant improvement versus placebo after 48 Weeks in the ANAVEX2-73-AD-004 DB trial by 36.3% for the key endpoints, ADAS-Cog13, and 27.6% for CDR-SB, respectively, a further, also significant, improvement was observed in the prespecified analysis of SIGMAR1 wild-type (WT) carriers, the ABCLEAR1 population.
Compared to the ITT population, the ABCLEAR1 population demonstrated additional and consistent improvement versus placebo. ADAS-Cog13 and CDR-SB for the total blarcamesine group improved by 49.8% and 33.6%, respectively, and for the 30 mg blarcamesine group by 49.1% and 35.5%, respectively.
For the 30 mg blarcamesine group, serious treatment-emergent adverse events occurred in 10 participants (12.7%) receiving blarcamesine and in 6 participants (9.1%) receiving placebo.
Price Action: AVXL stock is up 1.61% at $11.35 during the premarket session at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46745285/meta-cfo-susan-li-says-company-may-tap-external-financing-for-2026-ai-infrastructure-as-capex-heads-toward-100-billion" target="_blank" rel="noreferrer noopener">Meta CFO Susan Li Says Company May Tap External Financing For 2026 AI Infrastructure As CapEx Heads Toward $100 Billion</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

General

AVXL

Anavex Life Sciences: Early Blarcamesine Treatment Cuts Alzheimer's Progression by 20 Months

Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) reported quarterly earnings of $0.92 per share which missed the analyst consensus estimate of $0.94 by 1.81 percent. This is a 16.36 percent decrease over earnings of $1.10 per share from the same period last year. The company reported quarterly sales of $6.973 billion which beat the analyst consensus estimate of $6.389 billion by 9.15 percent. This is a 7.89 percent increase over sales of $6.463 billion the same period last year.

Southern Q2 Adj. EPS $0.92 Misses $0.94 Estimate, Sales $6.973B Beat $6.389B Estimate

B of A Securities analyst Justin Post maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $775 to $900.

B of A Securities Maintains Buy on Meta Platforms, Raises Price Target to $900

AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.07 by 26.29 percent. This is a 46.64 percent decrease over earnings of $2.53 per share from the same period last year. The company reported quarterly sales of $2.63 billion which beat the analyst consensus estimate of $2.50 billion by 5.41 percent. This is a 18.85 percent decrease over sales of $3.25 billion the same period last year.

AGCO Q2 Adj. EPS $1.35 Beats $1.07 Estimate, Sales $2.63B Beat $2.50B Estimate

Hilton Grand Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGV#NYSE">HGV</a>) reported quarterly earnings of $0.54 per share which missed the analyst consensus estimate of $0.76 by 28.95 percent. This is a 12.9 percent decrease over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $1.266 billion which missed the analyst consensus estimate of $1.358 billion by 6.77 percent. This is a 2.51 percent increase over sales of $1.235 billion the same period last year.

Comments

BTC Digital

BTC Digital (BTCT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO